Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial

Detailed Results To Be Presented Later

 
• By Mandy Jackson

Amgen said its KRAS G12C inhibitor Lumakras (sotorasib) bested docetaxel in a Phase III clinical trial on the primary endpoint of progression-free survival in second-line-plus non-small cell lung cancer.

lungs infographic vector illustration
Amgen has multiple monotherapy and combination therapy studies of Lumakras under way in lung and other cancers • Source: Shutterstock

More from Clinical Trials

More from R&D